Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.32
-2.4%		$0.54
$0.29
▼
$15.00
$53.25M-0.151,952 shs74,680 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$10.10
-5.3%		$10.63
$9.69
▼
$22.55
$200.25M0.99197,125 shs315,281 shs
PepGen, Inc. stock logo
PEPG
PepGen
$2.99
+0.3%		$2.01
$1.13
▼
$7.80
$207.09M1.891.05 million shs612,362 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$12.84
+4.1%		$12.38
$11.13
▼
$16.77
$219.64MN/A120,809 shs176,079 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
0.00%-22.91%-28.09%-63.84%+31,999,900.00%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
0.00%-9.42%-4.81%-3.81%-27.65%
PepGen, Inc. stock logo
PEPG
PepGen
0.00%+4.91%+32.89%+92.90%+164.60%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
0.00%+4.05%+5.59%-2.95%-72.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.32
-2.4%		$0.54
$0.29
▼
$15.00
$53.25M-0.151,952 shs74,680 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$10.10
-5.3%		$10.63
$9.69
▼
$22.55
$200.25M0.99197,125 shs315,281 shs
PepGen, Inc. stock logo
PEPG
PepGen
$2.99
+0.3%		$2.01
$1.13
▼
$7.80
$207.09M1.891.05 million shs612,362 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$12.84
+4.1%		$12.38
$11.13
▼
$16.77
$219.64MN/A120,809 shs176,079 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
0.00%-22.91%-28.09%-63.84%+31,999,900.00%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
0.00%-9.42%-4.81%-3.81%-27.65%
PepGen, Inc. stock logo
PEPG
PepGen
0.00%+4.91%+32.89%+92.90%+164.60%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
0.00%+4.05%+5.59%-2.95%-72.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALPS
ALPS Group Inc Ordinary Share
1.00
SellN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.22
Hold$20.50102.97% Upside
PepGen, Inc. stock logo
PEPG
PepGen
2.71
Moderate Buy$11.50284.62% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.29
Hold$63.85397.24% Upside

Current Analyst Ratings Breakdown

Latest ALPS, KROS, RNA, and PEPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
8/12/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/6/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$25.00
8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$20.00 ➝ $18.00
8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$30.00 ➝ $23.00
8/3/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E-) ➝ Sell (E)
7/29/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/6/2026
ALPS
ALPS Group Inc Ordinary Share
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/19/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/18/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$25.00
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALPS
ALPS Group Inc Ordinary Share
$4.86M10.96N/AN/A($3.10) per share-0.10
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$244.06M0.82$4.53 per share2.23$13.23 per share0.76
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/A$1.73 per shareN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$35.84M6.13N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALPS
ALPS Group Inc Ordinary Share
-$980K$0.330.97N/AN/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$87.01M-$3.70N/AN/AN/A-256.60%-21.40%-19.79%11/4/2026 (Estimated)
PepGen, Inc. stock logo
PEPG
PepGen
-$89.65M-$1.31N/AN/AN/AN/A-51.01%-43.49%N/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A-$0.97N/AN/AN/AN/AN/AN/AN/A

Latest ALPS, KROS, RNA, and PEPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$1.42-$1.18+$0.24-$1.18$0.67 million$3.00 million
8/6/2026Q2 2026
PepGen, Inc. stock logo
PEPG
PepGen
-$0.2845-$0.26+$0.0245-$0.26N/AN/A
8/3/2026Q2 2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.34-$1.45-$0.11-$1.45$0.81 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
21.96
21.96
PepGen, Inc. stock logo
PEPG
PepGen
N/A
13.36
14.98
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
13.04
13.04

Institutional Ownership

CompanyInstitutional Ownership
ALPS
ALPS Group Inc Ordinary Share
27.90%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
PepGen, Inc. stock logo
PEPG
PepGen
58.01%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
ALPS
ALPS Group Inc Ordinary Share
25.52%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
12.60%
PepGen, Inc. stock logo
PEPG
PepGen
1.30%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALPS
ALPS Group Inc Ordinary Share
N/A166.40 million123.94 millionN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
10019.83 million17.33 millionOptionable
PepGen, Inc. stock logo
PEPG
PepGen
3069.26 million68.36 millionNot Optionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
19017.11 million16.45 millionOptionable

Recent News About These Companies

Avidity Biosciences' (RNA) Buy Rating Reaffirmed at HC Wainwright
August 14 at 1:47 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-rna-buy-rating-reaffirmed-at-hc-wainwright-2026-08-14/
Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results
August 13 at 9:10 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-nasdaqrna-issues-earnings-results-2026-08-13/
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
August 13 at 4:44 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-reports-second-quarter-2026-financial-results-302851394.html
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
August 13 at 8:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration-302850610.html
Q3 Earnings Estimate for RNA Issued By HC Wainwright
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-earnings-estimate-for-rna-issued-by-hc-wainwright-2026-08-10/
Avidity Biosciences (NASDAQ:RNA) Research Coverage Started at HC Wainwright
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949734
Avidity Biosciences (NASDAQ:RNA) Now Covered by HC Wainwright
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-nasdaqrna-now-covered-by-hc-wainwright-2026-08-06/
Avidity Biosciences (RNA) Projected to Release Quarterly Earnings on Thursday
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943874
Avidity Biosciences (RNA) Expected to Announce Quarterly Earnings on Thursday
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-rna-expected-to-announce-quarterly-earnings-on-thursday-2026-08-06/
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Hold" from Brokerages
August 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30941791
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Analysts
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-inc-nasdaqrna-receives-average-recommendation-of-hold-from-analysts-2026-07-31/
Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average - Here's Why
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-nasdaqrna-stock-price-crosses-below-200-day-moving-average-heres-why-2026-07-22/
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302830029.html
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
July 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-atr-1072-for-treatment-of-prkag2-syndrome-302824844.html
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302808194.html
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
June 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/novartis-trial-wins-highlight-rhapsido-100916277.html
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
June 12, 2026  |  biopharmadive.comB
Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-reports-first-quarter-2026-financial-results-302772898.html
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
April 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration-302751102.html
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302748022.html
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
March 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/novartis-uses-us-bond-issue-170403727.html?pl2=world-indices-news_fltrd-strs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
First Internet Bancorp logo illuminated on a glass panel beside a bank card and smartphone with financial charts.
System Upgrade: First Internet Bancorp Options Surge
By Jeffrey Neal Johnson | August 4, 2026
Stack of office folders stamped “UPGRADED,” symbolizing rising analyst ratings for stocks like Micron in 2026.
These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
By Leo Miller | August 10, 2026
Walt Disney logo mounted on a wall beside a display featuring a castle model, film reel, and books.
Disney Sets Up for a Magical Year in 2027
By Thomas Hughes | August 6, 2026
Intel logo glowing above a detailed microchip surface in a high-tech semiconductor lab.
Intel Earnings Reveal Whether the Chip Selloff Created a Buy
By Chris Markoch | July 24, 2026
Illuminated Marriott logo and sign at the entrance of a hotel building at dusk.
Marriott’s Earnings Drop May Be Missing the Bigger Fee Growth Story
By Chris Markoch | August 4, 2026

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.32 -0.01 (-2.44%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.32 0.00 (0.00%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$10.10 -0.56 (-5.25%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$10.10 +0.00 (+0.01%)
As of 08/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

PepGen stock logo

PepGen NASDAQ:PEPG

$2.99 +0.01 (+0.34%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.99 0.00 (0.00%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$12.84 +0.51 (+4.14%)
As of 08/14/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas